CRVO
CervoMed Inc. (NASDAQ)
Healthcare — Biotechnology
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $34.16M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.53 |
| EPS (TTM) | $-3.28 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -132.76% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $19.50 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 62.9 |
| Beta | -4.54 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.13 |
| 52-Week Low | $2.13 |
| 50-Day Avg | $3.40 |
| 200-Day Avg | $5.76 |
| Avg Volume | $5.69M |
| Volume | 322.9K |
Performance Analysis
BULLISHCRVO shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report